MedAdvisor (ASX: MDR)

Following a notable US performance, integrating conversational AI and increased pharmacy transaction fees in Australia, medication management platform MedAdvisor Solutions (ASX: MDR) has reported a strong third quarter in FY24.  The December to February period in the US is typically the flu season, placing importance on getting vaccinated. This proved beneficial for MedAdvisor. In the

Covid-19 reimagined the world’s approach to healthcare. While it put excessive strain on healthcare employees, it urged companies and governments to think outside the box and develop a more sustainable system for the post-pandemic world. Of course, that looked different for everyone.  For countries like Estonia and the US, it entailed boosting telehealth services. For

While Australia enjoys the freedom of restrictions opening up and a substantial decrease in the COVID-19 deaths, vaccination rates across various States in the US remain dangerously low which has prompted one big pharma company to engage medtech company MedAdvisor (ASX: MDR) to slay the anti-vaxxers.  For the unnamed big pharma company which has a

Australian medtech company MedAdvisor (ASX: MDR) has received a major boost in confidence following an oversubscribed capital raise which included an $11m investment from U.S healthcare solutions provider HMS (NASDAQ: HMSY).  The investment from HMS comes alongside a further $6m raised from institutional investors bringing their total funds raised to $17m, all at an Offer